Westfield Capital Management Co. LP Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Westfield Capital Management Co. LP increased its stake in Lantheus Holdings by 2.2%, owning approximately 2.32% of the company, valued at $155 million.
• High institutional ownership is noted with 99.06% of Lantheus stock held by institutional investors, including significant increases from Janus Henderson Group PLC and Farallon Capital Management LLC.
• Analysts have a consensus rating of "Moderate Buy" for Lantheus, with target prices adjusted, reflecting mixed investor expectations after recent earnings results.

Westfield Capital Management Co. LP raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,589,145 shares of the medical equipment provider's stock after purchasing an additional 34,052 shares during the quarter. Westfield Capital Management Co. LP owned approximately 2.32% of Lantheus worth $155,101,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State of Michigan Retirement System grew its stake in shares of Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock worth $1,620,000 after buying an additional 100 shares during the last quarter. Signaturefd LLC lifted its holdings in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the period. Foundry Partners LLC increased its holdings in Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Lantheus by 2.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after acquiring an additional 139 shares during the period. Finally, Moody National Bank Trust Division grew its stake in shares of Lantheus by 1.0% in the 1st quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after buying an additional 141 shares during the period. Institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LNTH. William Blair restated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. B. Riley lowered their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Truist Financial lowered their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $131.20.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Lantheus Stock Down 28.6%

NASDAQ LNTH traded down $20.76 during mid-day trading on Wednesday, reaching $51.87. The stock had a trading volume of 13,951,981 shares, compared to its average volume of 1,069,187. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The stock has a market cap of $3.59 billion, a PE ratio of 14.74 and a beta of 0.14. The company has a fifty day moving average price of $77.54 and a 200 day moving average price of $87.67. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The firm had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The company's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 earnings per share. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.